#VisualAbstract: Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Tag: glioma
![Addition of bevacizumab fails to benefit overall survival in newly diagnosed glioblastoma [RTOG 0825 trial]](https://www.2minutemedicine.com/wp-content/uploads/2014/02/AFIP-00405558-Glioblastoma-Radiology-e1381685577283-350x250.jpg)
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
1. Median progression-free survival was shown to be 27.7 months in the vorasidenib group vs 11.1 months in the placebo ...
Dabrafenib plus trametinib provides clinically important response rates in BRAF-mutated gliomas
1. Response to treatment was noted in 33% of the high-grade glioma cohort and 69% of the low-grade cohort. 2. ...
Immunovirotherapy showed acceptable adverse-event profile in pediatric high-grade gliomas
1. Treatment with herpes simplex virus type 1 oncolytic virotherapy was shown not to demonstrate serious adverse events in pediatric ...
#VisualAbstract: Carboplatin holds potential as an adjunct therapy for recurrent high-grade glioma treatment
1. Carboplatin, given through intracerebral, convection-enhanced delivery, may be a viable adjunct in recurrent high-grade glioma treatment. Evidence Rating Level: 1 ...
Radiation plus chemotherapy confers survival benefit compared to radiation alone in low-grade gliomas
1. In grade 2 glioma patients younger than 40 years old that have undergone subtotal tumour resection, or in patients ...
Integrative genomic analysis promising for diagnostic subtyping of lower-grade glioma
1. Analysis of genomewide data revealed three robust, nonoverlapping, and clinically significant tumor classes based on presence of IDH mutation ...
Danish case control study links oral contraceptives with glioma
1. Hormonal contraception use was more prevalent among women who developed glioma, a brain tumor, to women without glioma. 2. ...